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G
lucokinase (hexokinase IV) has a major role in
the control of blood glucose homeostasis be-
cause it is the predominant hexokinase ex-
pressed in the liver, has a very high control
strength on hepatic glucose disposal (1), and is the glucose
sensor for insulin secretion in pancreatic -cells (2).
Glucokinase is currently considered a strong candidate
target for antihyperglycemic drugs for type 2 diabetes
(2–4). This is supported by the impact of mutations in the
glucokinase gene on blood glucose concentration in hu-
mans. Inactivating mutations that lower the enzyme afﬁn-
ity for glucose or compromise glucokinase expression
cause diabetes (maturity onset diabetes of the young type
2), whereas activating mutations lower blood glucose (2).
Pharmacological activators of glucokinase (GKAs) that
mimic the effect of activating mutations represent a poten-
tial novel strategy for antihyperglycemic therapy (2–4).
Type 2 diabetes is associated with defective regulation
of hepatic glucose metabolism, involving elevated glucose
production in euglycemic conditions and subnormal clear-
ance of glucose by the liver after a meal because of
delayed suppression of hepatic glucose production and
impaired conversion of glucose to glycogen (5,6). This
inefﬁcient clearance of glucose by the liver is due at least
in part to impaired regulation of glucose production and
usage by hyperglycemia, a process sometimes described
as decreased “autoregulation” or “glucose effectiveness”
(7). Whether the defect in diabetes in humans involves
decreased glucokinase activity is not established. Hepatic
glucokinase activity was shown to be either elevated in
newly diagnosed type 2 diabetic patients (8) or decreased
in obese subjects with diabetes (9). Hepatic glucokinase is
regulated by an inhibitory protein (glucokinase regulatory
protein [GKRP]) that binds glucokinase with high afﬁnity
at basal glucose concentrations (5 mmol/l) and sequesters
glucokinase in the nucleus in an inactive state (1,10). In
the postprandial state, hyperglycemia causes dissociation
of glucokinase from GKRP and translocation to the cyto-
plasm (Fig. 1). It could be speculated that decreased
“glucose effectiveness” in type 2 diabetes in humans may
involve decreased glucokinase expression or impaired
regulation by GKRP, as occurs in animal models of insulin
resistance (11,12), in addition to other metabolic defects.
For hepatic glucokinase to be an effective target for
antihyperglycemic drugs (GKAs) in type 2 diabetes in
humans, three essential criteria must be met. First, there
must be sufﬁcient expression of endogenous glucokinase
such that the GKAs can elicit a substantial increment in
glucose phosphorylating capacity. Second, glucokinase
must have a high control strength on hepatic glucose
disposal in the dysregulated diabetic state, such that
increments in glucokinase activity caused by the GKAs
relay corresponding changes in glucose ﬂux. A third,
important criterion is that glucokinase activation in diabe-
tes must not have untoward metabolic effects, such as
excessive enhancement of hypertriglyceridemia (13) or
accumulation of fat in the liver that would further aggra-
vate hepatic insulin resistance. Although several studies
have demonstrated the efﬁcacy of liver-speciﬁc up regula-
tion or down regulation of glucokinase activity in nondia-
betic models (rev. in 3,14), there have been few detailed,
thorough studies based on either glucokinase overexpres-
sion or pharmacological activation that have speciﬁcally
addressed these issues in models of diabetes with insulin
resistance.
Torres et al. (15) report a detailed study of the effect of
overexpression of glucokinase in liver on glucose turnover
in the Zucker diabetic fatty (ZDF) rat (20 weeks old) in
basal conditions and during a hyperglycemic clamp. The
ZDF rat is characterized by increased body weight and
progressive insulin resistance, beginning at 7 weeks and
leading to development of overt diabetes after 10 weeks.
Hepatic glucokinase activity was elevated before the de-
velopment of diabetes (at 7–10 weeks) but declined sub-
sequently in parallel with the fall in circulating insulin to
an activity level about one third that of nondiabetic
controls at 20 weeks. GKRP expression remained constant
and, accordingly, the glucokinase-to-GKRP ratio (and
thereby the hepatocellular afﬁnity for glucose [1]) paral-
leled the changes in glucokinase expression. The develop-
ment of diabetes was associated with increased
endogenous glucose production, glucose cycling between
phosphorylation of glucose and dephosphorylation of glu-
cose-6-phosphate, and increased ﬂux through glucose-
6-phosphatase, determined from the sum of glucose cy-
cling and endogenous glucose production.
Torres et al. (15) overexpressed glucokinase in the liver
of ZDF rats by treatment with an adenoviral vector at
19–20 weeks. The viral titers used enabled selection of
two groups of treated diabetic rats: one with glucokinase
activity that was restored to the level of nondiabetic
controls (threefold increase) and another with activity
twice that of nondiabetic controls (sixfold increase). The
hepatic glucose-6-phosphate content and glycogen synthe-
sis from glucose (Fig. 1) closely paralleled glucokinase
expression and were normalized in the group with re-
stored glucokinase activity and further increased in the
From the Institute of Cellular Medicine, The Medical School, Newcastle
University, Newcastle upon Tyne, U.K.
Corresponding author: Loranne Agius, loranne.agius@ncl.ac.uk.
DOI: 10.2337/db08-1470
© 2009 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
See accompanying original article, p. 78.
COMMENTARY
18 DIABETES, VOL. 58, JANUARY 2009group with twofold elevation of glucokinase. The latter
indicates that the high control strength of glucokinase on
both the glucose-6-phosphate content and glycogen syn-
thesis is preserved in the diabetic model. In the experi-
mental group with restored glucokinase activity,
hyperglycemia was partially corrected (60%), and elevated
endogenous glucose production and ﬂux through glucose
6-phosphatase, both before and during the hyperglycemic
clamp, were partially rectiﬁed. In the group with overcom-
pensated glucokinase activity (twice normal), the correc-
tion of hyperglycemia was further improved (87%), though
still not completely normalized, and endogenous glucose
production was still elevated in basal conditions (before
the clamp) but was suppressed during the hyperglycemic
clamp (similar to nondiabetic controls). While these re-
sults demonstrate the efﬁcacy of glucokinase overexpres-
sion in reversing hyperglycemia in diabetes, they also
show that overcompensation of glucokinase activity to
twofold above that for nondiabetic controls is necessary to
achieve glycemic control and near-normal endogenous
glucose production. This indicates that the defect in the
diabetic model is clearly not conﬁned to glucokinase
regulation and, accordingly, overcompensation of glucoki-
nase activity is necessary to achieve glycemic control.
An important issue is whether treatments that raise
hepatic glucokinase activity to a sufﬁcient level to achieve
adequate glycemic control in diabetes cause excessive
elevation in plasma and hepatic triglycerides (Fig. 1) by
stimulation of glycolysis and lipogenesis. A previous study
demonstrated that overexpression of glucokinase by six-
fold in nondiabetic rats raised plasma triglycerides and
cautioned against possible hypertriglyceridemia resulting
from glucokinase activation (13). However, other studies
involving a more modest increase in hepatic glucokinase
activity (less than twofold) did not show abnormalities in
plasma triglycerides on either a normal diet or a high-fat
diet (rev. in [3]). At 20 weeks the ZDF rat has very marked
hypertriglyceridemia (15). In this model, glucokinase over-
expression was associated with markedly raised lactate
concentrations and a trend toward elevated plasma tri-
glycerides (15). It is noteworthy, however, that in 20-week
ZDF rats, impaired clearance of triglycerides is an impor-
tant contributing factor to excessive triglyceridemia (16).
Further studies are needed on the effects of glucokinase
overexpression or activation with GKAs on both plasma
triglycerides and hepatic triglycerides in experimental
animal models where plasma triglycerides correlate with
hepatic triglyceride secretion and in clinical studies.
At this point, some lessons can be learned from the
recent genome-wide analysis studies that identiﬁed asso-
ciations among two common GKRP gene (GCKR) variants
(an intron and a coding single nucleotide polymorphism)
and elevated serum triglycerides and lower fasting plasma
glucose (17–20). In type 2 diabetes, hypertriglyceridemia
generally correlates with hyperglycemia because conver-
sion of glucose to triglyceride is a major hepatic route of
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FIG. 1. Hepatic glucose metabolism. In the postabsorptive state, glucokinase (GK) is sequestered in the nucleus bound to GKRP and the liver
maintains blood glucose homeostasis by glucose production (red arrows) by glycogenolysis from glycogen and by gluconeogenesis from lactate
and other gluconeogenic substrates. In the postprandial state (blue arrows), a rise in blood glucose concentration in the portal vein >5 mmol/l
causes dissociation of glucokinase from GKRP and translocation of glucokinase to the cytoplasm, resulting in increased glucose phosphorylation
to glucose-6-phosphate (G6P) and conversion to glycogen, lactate, and triglyceride (TG). If the production of triglyceride via glycolysis to
pyruvate and synthesis of fatty acids exceeds the VLDL secretion capacity, triglyceride accumulates in the hepatocyte. Pharmacological GKAs
mimic the effect of glucose in causing translocation of glucokinase to the cytoplasm, and they also directly increase glucokinase activity. F6P,
fructose-6-phosphate; Glc, glucose; G6P, glucose-6-phosphate; G6Pase, glucose-6-phosphatase.
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DIABETES, VOL. 58, JANUARY 2009 19glucose disposal (Fig. 1). However, the inverse correlation
between plasma triglycerides (elevated) and glucose (low-
ered), in association with two GKRP variants (rs780094
and rs1260326), suggests that the increased glucose phos-
phorylation capacity (inferred from the lowering of plasma
glucose because no molecular characterization of the
human GKRP variants is available as yet) correlates with
elevated triglycerides, as was indicated by glucokinase
overexpression (13). Nonetheless, at least in some circum-
stances (20), the beneﬁts of blood glucose lowering may
outweigh the risks posed by higher triglycerides. Likewise,
although targeting hepatic glucokinase in type 2 diabetes
may enhance plasma triglycerides through an inevitable
physiological process, the beneﬁts of improved glycemic
control might still outweigh the risks of elevated triglyc-
erides. Alternatively, the latter can be treated by combina-
tion therapy. Thorough scrutiny of the impact of novel
treatments on hepatic and plasma triglycerides remains of
paramount importance.
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